159499-97-5

Upstream product

• 942296-83-5 C₁₇H₁₄O₆Br₂ 
• 77-78-1 dimethyl sulfate 
• 130883-74-8 3,3'-dibromo-5,5'-dicarboxy-4,4'-dihydroxydiphenylmethane 

Downstream Products

• 159499-99-7 methyl-3-bromo-5-(1-(5-bromo-4-methoxy-3-(methoxycarbonyl)phenyl)hept-1-enyl)-2-methoxybenzoate 
• 159499-98-6 [3',3''-dibromo-4',4''-dimethoxy-5',5''-di(methoxycarbonyl)diphenyl]methanone 

Relevant academic research and scientific papers

Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors

The alkenyldiarylmethanes (ADAMs) are currently being investigated as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) of potential value in the treatment of HIV infection and AIDS. During the course of these studies, a number of ADAM analog

Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors

Several novel alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors were synthesized. The most potent of these proved to be 3',3'-dibromo-4',4'-dimethoxy-5',5'-bis(methoxycarbonyl)-1,1-diphenyl-1- heptene (8). ADAM 8 inhibited